← Back to all trials
Recruiting
NCT06480591
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Conditions: Myeloproliferative Neoplasm
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Enrollment: 35
Sponsor: Wake Forest University Health Sciences
Location: Atrium Health Levine Cancer Charlotte North Carolina
Summary
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Eligibility Criteria
Inclusion Criteria:
* Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
* Age ≥ 18 years at the time of enrollment
* Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
* CALR-positive genetic mutation
Exclusion Criteria:
\- Diagnosis of MPN with JAK2 V617F mutation
Source: ClinicalTrials.gov (NCT06480591). StuddyBuddy aggregates publicly available trial information.
